Lebrikizumab aids atopic dermatitis with, without comorbidities

Among patients with moderate to severe atopic dermatitis, atopic comorbidities did not change the benefits seen with lebrikizumab, according to data published in Annals of Allergy, Asthma & Immunology.
“Clinician awareness of atopic comorbidities and the additional impact that these conditions have on patients with AD is critical for shared decision-making around AD treatments and patient-centered care overall,” Ellen R. Sher, MD, FACAAI, physician at Allergy Partners of New Jersey and clinical associate professor at Rutgers Robert Wood Johnson Medical School, and colleagues wrote.
In a





